BRL Medicine Inc. Wins '2021 China Most Promising Innovative Biopharmaceutical Company Award'

SHANGHAI, Oct. 13, 2021 /PRNewswire/ -- Oct. 11-12, 2021, the two-dayBPID 2021 Shanghai (Minhang) Biopharmaceutical Industry Innovation SummitSuccessfully held in Hongqiao, Shanghai. BRL Medicine Inc. was honored with the "2021 Annual Award for Most Promising Growth in China's Innovative Biopharmaceuticals". The conference organizers cordially invited Professor Liu Mingyao, Chairman of BRL Medicine, and Dr. Gao Yang, Chief Strategy Officer, to participate in the summit forum as representatives of outstanding innovative pharmaceutical enterprises in China and to attend the award ceremony.

500+ Innovative Biopharmaceutical Companies Gather

Hosted by the Shanghai Association for Science and Technology and the Minhang District People's Government, Shanghai, and themed "Biomedicine Empowering High-Quality Development in Minhang," this conference explores trending topics such as local biopharmaceutical innovation, cutting-edge technologies for innovative biologics, and the preclinical research and regulatory submission of biologics, aiming to consolidate efforts to build an industrial cluster on a 100-billion-yuan scale and thereby accelerate the development of a pioneering demonstration hub for biopharmaceutical industry innovation that radiates across the Yangtze River Delta, serves China nationwide, and connects globally.

Conference Venue

Industry Leaders Gather, BRL Medicine Invited to Share Insights

At the conference, Professor Liu Mingyao, Chairman of BRL Medicine Inc., and Dr. Gao Yang, Chief Strategy Officer, were invited as representatives of outstanding innovative pharmaceutical companies in China to share the latest advances in gene therapy and cell therapy, and to moderate the summit forum on clinical research and regulatory submissions.

Speech by Professor Liu Mingyao, Chairman of BRL Medicine

Professor Liu Mingyao, Chairman of BRL Medicine, delivered a speech at the conference,Given the numerous limitations and challenges still present in the development of current cell and gene therapy drugs, such as high costs, lengthy manufacturing cycles, and limited efficacy in solid tumors, how can companies overcome these industry barriers and pain points to achieve the clinical translation of gene editing?

Professor Liu Mingyao stated: “In the fields of cell therapy and gene therapy, whether in basic research or clinical translation, BRL Medicine has consistently maintained a leading position internationally, and continuously drives the rapid iterative updates of its R&D products based on patient needs and clinical feedback. In recent years, BRL Medicine has remained dedicated to original technology R&D, and has successfully established five proprietary technology platforms with independent intellectual property rights: a gene editing technology innovation platform, a hematopoietic stem cell platform, a non-viral CAR-T platform, a universal cell platform, and an enhanced T cell platform. For instance, the upgraded technology platform for BRL Medicine's CAR-T pipeline--the non-viral CAR-T (Quikin CAR-T^®）platform, leveraging CRISPR gene-editing technology to achieve gene knockout and the site-specific, stable integration of CAR constructs in a single step. To date, BRL Medicine has achieved a groundbreaking milestone: the world's first PD-1 knockout, non-viral site-specific integrated CAR-T therapy for the treatment of lymphoma and severe β-thalassemia. Looking ahead, BRL Medicine will continue to uphold an open, collaborative, and win-win philosophy, partnering with global innovative biopharmaceutical ecosystem enterprises to accelerate the clinical translation and commercialization of novel therapeutics. By driving innovation through gene editing, we are committed to developing breakthrough therapies that benefit all of humanity.”

Hosted by Dr. Gao Yang, Chief Strategy Officer of BRL Medicine

Additionally, Dr. Yang Gao, Chief Strategy Officer of BRL Medicine, was invited to hoststated at the “China-US-EU Biologics Registration and Submission Conference”:“Gene and cell therapy products are characterized by rapid technological iteration, complex mechanisms of action, and swift industry development, prompting continuous adjustments and reforms in regulatory systems worldwide. As applicants, it is essential to closely monitor regulatory developments, keep abreast of regulations and technical guidelines, and maintain timely communication with regulatory authorities to ensure the successful development of gene and cell therapy products within the regulatory framework for the benefit of patients. Consistently, BRL Medicine has upheld a rigorous and meticulous approach to CMC, strictly controlling product quality to effectively ensure product efficacy.”

Once Again ObtainedRecognized BRL MedicineBiotech Company Makes the List

On the 11th, at the invitational gala dinner—the “Starlight Awards” ceremony—BRL Medicine was honored with the “2021 Annual Award for the Most Promising Growth in China’s Innovative Biopharmaceuticals” by virtue of its outstanding industry influence, sustained innovation capabilities, and high growth potential. Dr. Li Wei, Vice President of Medicine and Clinical Affairs at BRL Medicine, took the stage to accept the award on behalf of the company.

Award Ceremony

Regarding this award, BRL MedicineMr. Zaixi Xi, CEO, stated:“This award not only affirms BRL Medicine’s rapid growth over the past few years, but also recognizes the company’s capabilities in innovative R&D and translational operations. Since its establishment, BRL Medicine has maintained a global market perspective and established a comprehensive presence in the gene and cell therapy sectors. Moving forward, BRL will continue to champion technological innovation, striving to overcome core challenges and critical technological bottlenecks in gene and cell therapy. Furthermore, we will sustain our comprehensive competitiveness across multiple dimensions, including global commercialization, business model innovation, brand management, strategic partnerships, and public relations. We are confident that in the near future, BRL Medicine will leverage gene editing technology to drive innovation and develop breakthrough therapies, ultimately emerging as a globally leading cell and gene therapy company!”

# About BRL Medicine

BRL Medicine Inc. is committed to becoming a globally leading gene and cell therapy enterprise in the new era of business civilization. Guided by its mission to "lead innovation through gene editing, develop breakthrough therapies, and benefit all of humanity," and relying on its proprietary R&D center and the "Shanghai Gene Editing and Cell Therapy Research Center" co-established with universities, the company has generated over 100 patent achievements in the past five years. Five projects are conducting investigator-initiated clinical trials at eight renowned hospitals, and multiple projects have entered the Investigational New Drug (IND) application stage. Among them, projects such as gene-edited therapy for β-thalassemia, PD-1 knockout non-viral site-specific integration CAR-T, and UCART have already achieved outstanding clinical outcomes, demonstrating global leadership, and areNature Medicine、Nature biotechnologyand other renowned academic journals, and has published multiple academic papers.

Currently, BRL Medicine has established five proprietary technology platforms with independent intellectual property rights: gene editing tool development, hematopoietic stem cell gene editing, non-viral site-specific integration CAR-T platform, universal cell therapy platform, and enhanced T cell platform. Equipped with a 6,000-square-meter GMP pilot manufacturing facility and an operational team of nearly 200 professionals, the company effectively ensures the rapid translation and application of innovative research outcomes. Driven by patient needs and clinical feedback, BRL Medicine continuously accelerates the iteration and optimization of its R&D products. Upholding the principles of openness, sharing, and win-win collaboration, BRL Medicine works alongside innovative biopharmaceutical enterprises within the global ecosystem to expedite the translation and clinical implementation of novel therapeutics, ultimately benefiting patients with genetic diseases and malignant tumors worldwide.Tumor patients.